Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436110 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma
A Phase 3 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
- 20
- Study locations
NCT01436110 is a Phase 3 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 351 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01436110, a Phase 3 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticosteroids
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluticasone furoate 50mcg
- DRUG Fluticasone propionate 100mcg
Study Locations (20)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Rolling Hills Estates
- GSK Investigational Site - Sacramento
- GSK Investigational Site - San Jose
Florida
- GSK Investigational Site - Aventura
- GSK Investigational Site - Clearwater
- GSK Investigational Site - Hialeah
- GSK Investigational Site - Orlando
Texas
- GSK Investigational Site - Corsicana
- GSK Investigational Site - El Paso
- GSK Investigational Site - Waco
Louisiana
- GSK Investigational Site - Metairie
- GSK Investigational Site - Sunset
Maryland
- GSK Investigational Site - Bethesda
Missouri
- GSK Investigational Site - Columbia
Nevada
- GSK Investigational Site - Las Vegas
New Jersey
- GSK Investigational Site - Brick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01436110
The ClinicalTrials.gov registry entry for NCT01436110 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (78% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01436110 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT01436110 about?
NCT01436110 is a clinical study titled "Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma". A randomised, double-blind, double-dummy, placebo controlled multi-centre study to evaluate the efficacy and safety of fluticasone furoate inhalation powder and fluticasone propionate inhalation powder in the treatment of asthma in adults and adolescents not currently treated with inhaled corticoste...
What is the current status of trial NCT01436110?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2011-09. Estimated completion is 2012-09.
What conditions does trial NCT01436110 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01436110?
The interventions under investigation include: Placebo (DRUG), Fluticasone furoate 50mcg (DRUG), Fluticasone propionate 100mcg (DRUG).
Who is sponsoring clinical trial NCT01436110?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01436110 being conducted?
This trial has 20 study locations across California, Florida, Louisiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.